Glenmark Pharmaceuticals ltd — M&A Activity 2023

Jul 20, 2023

==> picture [17 x 10] intentionally omitted <==

==> picture [18 x 11] intentionally omitted <==

==> picture [149 x 45] intentionally omitted <==

July 20, 2023

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

To, The Manager – Listing, The National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In furtherance to our earlier intimation dated 30th April, 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22nd June, 2023 (certified copy of which was received on 19th July 2023), has approved the Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries of Aarogya Bharat Digital LLP (earlier known as DigiHealth Technologies LLP), which in turn is a wholly‐owned subsidiary of ABCD Technologies LLP.

The Company owns 6.45% interest in ABCD Technologies LLP.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK VINAYAK KUBER Date: 2023.07.20 KUBER 17:23:24 +05'30' Harish Kuber

Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com